Trial Profile
Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 29 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2018 Planned End Date changed from 27 Jul 2018 to 27 Jan 2020.